Conazoles
Tóm tắt
This review provides a historical overview of the analog based drug discovery of miconazole and its congeners, and is focused on marketed azole antifungals bearing the generic suffix “conazole”. The antifungal activity of miconazole, one of the first broad-spectrum antimycotic agents has been mainly restricted to topical applications. The attractive in vitro antifungal spectrum was a starting point to design more potent and especially orally active antifungal agents such as ketoconazole, itraconazole, posaconazole, fluconazole and voriconazole. The chemistry, in vitro and in vivo antifungal activity, pharmacology, and clinical applications of these marketed conazoles has been described.
Từ khóa
Tài liệu tham khảo
Schiller, 2007, Posaconazole: An Extended- Spectrum Triazole Antifungal, Clin. Ther., 29, 1862, 10.1016/j.clinthera.2007.09.015
Godefroi, 1969, The Preparation and Antimycotic Properties of Derivatives of 1-Phenethylimidazole, J. Med. Chem., 12, 784, 10.1021/jm00305a014
Godefroi, 1968, Reductive ring cleavage of 1,3-disubstituted imidazolium iodides by sodium borohydride, J. Org. Chem., 33, 860, 10.1021/jo01266a089
Tajana, 1981, Physico-Chemical, Structural and Analytical Studies on Fenticonazole, a New Drug with Antimycotic Properties, Arzneim.-Forsch./Drug Res., 31, 2127
Heeres, 1977, Antimycotic Imidazoles. 3. Synthesis and Antimycotic Properties of 1-[2-(Aryloxyalkyl)-2-phenylethyl]-1H-imidazoles, J. Med. Chem., 20, 1516, 10.1021/jm00221a033
Mixich, 1979, Ein Beitrag zur stereospezifischen Synthese von antimykotisch wirksamen Imidazolyloximäthern, Arzneim.-Forsch./Drug Res., 29, 1510
Walker, 1978, 1-[4-(4-Chlorophenyl)-2-(2,6-dichlorophenylthio)-n-butyl]-1H-imidazole Nitrate, a New Potent Antifungal Agent, J. Med. Chem., 21, 840, 10.1021/jm00206a028
Heeres, 1981, Imidazoles, 5, Synthesis and Antimycotic Properties of 1-[[2-Aryl-4(aralkyl)-1,3-dioxolan-2-yl]methyl]-1H-imidazoles, J. Med. Chem., 24, 1360, 10.1021/jm00143a019
Heeres, 1979, Antimycotic Imidazoles. Part 4. Synthesis and Antifungal Activity of Ketoconazole, a Potent Orally Active Broad-Spectrum Antifungal Agent, J. Med.Chem., 22, 1003, 10.1021/jm00194a023
Heeres, 1983, Antimycotic Azoles, 6, Synthesis and Antifungal Properties of Terconazole, a Novel Triazole Ketal, J. Med. Chem., 26, 611, 10.1021/jm00358a032
Heeres, 1984, Antimycotic Azoles. 7. Synthesis and Antifungal Properties of a Series of Novel Triazol-3-ones, J. Med. Chem., 27, 894, 10.1021/jm00373a015
Rippon, J.W., and Fromtling, R.A. (1993). Cutaneus Antifungal Agents, Marcel Decker Inc.
Saksena, 1996, Consise Asymmetric routes to 2,2,4-trisubstituted tetrahydrofurans via chiral titanium imide enolates: key intermediates towards synthesis of highly active azole antifungals Sch 51048 and Sch 56592, Tetrahedron Lett., 32, 5657, 10.1016/0040-4039(96)01203-8
Bently, P.H., and O’Hanlon, P.J. (1997). Anti-Infectives Recent Advances in Chemistry and Structure-Activity Relationships, The Royal Society of Chemistry.
Rippon, E.J.W., and Fromtling, R.A. (1993). Cutaneus Antifungal Agents, Marcel Dekker Inc.
Butters, 2001, Process Development of Voriconazole: A Novel Broad-Spectrum Triazole Antifungal agent, Org. Process Res. Dev., 5, 28, 10.1021/op0000879
Jevons, 1979, Antifungal Activity of Tioconazole (UK-20,349), a New Imidazole Derivative, Antimicrob. Agents Chemother., 15, 597, 10.1128/AAC.15.4.597
Veronese, 1981, Fenticonazole, a New Imidazole Derivative with Antibacterial and Antifungal Activity, Arzneim.-Forsch./Drug Res., 31, 2133
Graziani, 1981, Toxicological and Pharmacological Properties of Fenticonazole, a New Topical Antimycotic, Arzneim.-Forsch./Drug Res., 31, 2145
Costa, 1982, “In vitro” Antimycotic Activity of Fenticonazole (Rec 15/1476), Mykosen, 25, 47, 10.1111/j.1439-0507.1982.tb02716.x
Veronese, 1984, Fenticonazole: A New Antifungal Imidazole Derivative In vitro and In vivo Activity, Mykosen, 27, 194, 10.1111/j.1439-0507.1984.tb02020.x
Veronese, 1981, Antifungal activity of Fenticonazole in Experimental Dermatomycosis and Candidiasis, Arzneim.-Forsch./Drug Res., 31, 2137
Yoshida, 1984, Studies on Antifungal Activities of Sulconazole, Chemotherapy, 32, 477
Ortiz, 1992, Sertaconazole, A New Antifungal agent, Arzneim.-Forsch./Drug Res., 42, 689
Palacin, 2001, In vitro Activity of Sertaconazole, Ketoconazole, Fenticonazole, Clotrimazole and Itraconazole Against Pathogenic Vaginal Yeast Infections, Methods Find, Exp. Clin. Pharmacol., 23, 61
Rotstein, 1993, The Synthesis and Antifungal Activity of the Enantiomers of Butoconazole Nitrate, Tetrahedron Assymmetry, 4, 1521, 10.1016/S0957-4166(00)80353-5
Heeres, J. (1993, January 7-9). New Azole Compounds: From Hypnotics to Itraconazole, a Broad-Spectrum Antifungal Agent. Actualités Chim. Therapeut; Proceedings of 28emes Rencontre Internationales de Chimie Therapéutique, Toulouse, France.
Thienpont, 1979, Ketoconazole - a new broad-spectrum orally active antimycotic, Experientia, 35, 606, 10.1007/BF01960348
Rippon, J.W., and Fromtling, R.A. (1993). Cutaneus Antifungal Agents, Marcel Dekker Inc.
Dickinson, 1996, Novel antifungal 2-aryl-1-(1H-1,2,4-triazol-1-yl)butan-2-ol derivatives with high activity against Aspergillus fumigatus, Bioorg. Med. Chem. Lett., 6, 2031, 10.1016/0960-894X(96)00363-0
Thienpont, 1972, Miconazole, a Broad-Spectrum Antimycotic Agent with Antibacterial activity, Chemotherapy, 17, 392, 10.1159/000220875
Heel, 1980, Miconazole: A Preliminary Review of its Therapeutic Efficacy In Systemic Fungal Infections, Drugs, 19, 7, 10.2165/00003495-198019010-00002
Llosa, 1992, In vitro activity of cloconazole, sulconazole, butoconazole, isoconazole, fenticonazole, and five other antifungal agents against clinical isolates of Candida albicans and Candida spp., Mycopathalogia, 118, 15, 10.1007/BF00472565
Odds, 1985, Suppression of ATP in Candida albicans by imidazole and derivative antifungal agents, Sabouraudi: J. Med. Vet. Mycol., 23, 415, 10.1080/00362178585380611
Brugmans, 1972, Systemic antifungal potential, safety, biotransport and transformation of miconazole nitrate, Eur. J. Clin. Pharmacol., 5, 93, 10.1007/BF00561752
Lewi, 1976, Pharmacokinetic profile of intravenous miconazole in man. Comparison of normal subjects and patients with renal insufficiency, Eur. J. Clin. Pharmacol., 10, 49, 10.1007/BF00561549
Janssen, 1979, Miconazole, Pharmacological and Biochemical Properties of Drug Substances, Volume 2, 333
Thienpont, 1975, Biological and toxicological properties of econazole, a broad-spectrum antimycotic, Arzneim.-Forsch., 25, 224
Levine, 1976, R34000, a dioxolane imidazole in the therapy for experimental coccidioidomycosis, Chest, 70, 755, 10.1378/chest.70.6.755
Cartwright, 1978, Absorbtion of econazole from the human gastrointestinal tract, Curr. Chemothery: Proceedings of International Congress Chemotherapy, Volume 1, 231
Heel, 1978, Econazole: A Review of its Antifungal Activity and Therapeutic Efficacy, Drugs, 16, 177, 10.2165/00003495-197816030-00001
Drouhet, 1977, Treatment of pityriasis capitis (dandruff) with econazole nitrate, Acta Dermatovener, 57, 77
Kessler, 1979, Mikrobiologische Untersuchungen mit Isoconazolnitrat, einem Breitspectrum-Antimykoticum aus der Gruppe der Imidazol-Derivate, Arzneim.-Forsch./Drug Res., 29, 1344
Fromtling, 1988, Overview of Medically Important Azole Derivatives, Clin. Microbiol. Rev., 1, 187, 10.1128/CMR.1.2.187
Fark, 1982, Results of Isoconazol Nitrate Treatment of Vaginal Mycoses, Mykosen, 25, 629, 10.1111/j.1439-0507.1982.tb01932.x
Herms, 1988, Once-Daily-Application of Isoconazole as Cream, Solution and Spray: Comparative Studies on Patients with Dermatomycoses, Z. Hautkr., 63, 377
Weitgasser, 1979, Comparative Clinical Investigations with the New Antimycotic Agent Isoconazole Nitrate and its Combination with Diflucortolone-21-valerate in the Case of Inflammatory and Eczematised Dermatomycoses, Mykosen, 22, 177, 10.1111/j.1439-0507.1979.tb01738.x
Oyeka, 1992, Isoconazole Nitrate versus clotrimazole in foot and nail infections due to Hendersonula toruloidea, Scytalidium hyalinum and dermatophytes, Mycoses, 35, 357, 10.1111/j.1439-0507.1992.tb00894.x
Eschborn, 1993, Fenticinazole. A local antimycotic, Mykosen, 44, 34
Polak, 1982, Oxiconazole, a New Imidazole Derivative, Arzneim.-Forsch./Drug Res., 32, 17
Gebhart, 1984, In vitro Susceptibility Studies with Oxiconazole, Chemotherapy, 30, 244, 10.1159/000238275
Jegasothy, 1991, Oxiconazole Nitrate: Pharmacology, Efficacy, and Safety of a New Imidazole Antifungal Agent, Clin. Ther., 13, 126
Wagner, 1986, Vergleich der klinischen Wirksamkeit und Verträglichkeit von Oxiconazol nach 1x täglicher Applikation mit der nach 2x täglicher Application, Mykosen, 29, 280, 10.1111/j.1439-0507.1986.tb03785.x
Odds, 1980, Laboratory evaluation of antifungal agents: a comparative study of five imidazole derivatives of clinical importance, J. Antimicrob. Chemother., 6, 749, 10.1093/jac/6.6.749
Clissold, 1986, Tioconazole, A Review of its Antimicrobial Activity and Therapeutic Use in Superficial Mycoses, Drugs, 31, 29, 10.2165/00003495-198631010-00003
Krohn, 1983, Open Comparison of the Efficacy, Toleration and Safety of Tioconazole and Econazole in the 3-Day Treatment of Vaginal Candidiasis, Gynäk. Rdsch., 23, 29
Artner, 1983, Open Studies of the Efficacy, Tolerance, Systemic Absorbtion and Vaginal Persistence following a Single Application of Tioconazole Ointment in the Treatment of Patients with vaginal Candidosis, Gynäk. Rdsch., 23, 12
Clayton, 1982, Double Blind comparison of the efficacy of tioconazole and miconazole for the treatment of fungal infection of the skin orerythrasma, Clin. Exp. Dermatology, 7, 543, 10.1111/j.1365-2230.1982.tb02473.x
Seidman, 2005, An evaluation of butoconazole nitrate 2% Site Release vaginal cream (Gynazole-1) compared to fluconazole 150 mg tablets (Diflucan) in the time to releif of symptoms in patients with vulvovaginal candidiasis, Infect. Dis. Obstet. Gynecol., 13, 197, 10.1155/2005/453239
Palacin, 1992, In vitro Activity of Sertaconazole, Arzneim.-Forsch./Drug Res., 42, 699
Giusiano, 2005, Sertaconazole: updated review of a topical antifungal agent, Expert Rev. Anti Infect. Ther., 3, 333, 10.1586/14787210.3.3.333
Palacin, 1992, In vivo Activity of Sertaconazole in Experimental Dermatophytosis in Guinea Pigs, Arzneim.-Forsch./Drug Res., 42, 714
Pedragosa, 1992, Therapeutic Efficacy and Safety of the New Antimycotic Sertaconazole in the Treatment of Pityriasis versicolor, Arzneim.-Forsch./Drug Res., 42, 760
Tolman, 1986, Anticandidal Activities of Terconazole, a Broad-Spectrum Antimycotic, J. Antimicrob. Chemother., 29, 986, 10.1128/AAC.29.6.986
Tolman, 1985, In vitro Studies with Terconazole, Gynäk. Rdsch., 25, 12
Hirsch, 1989, Clinical Evaluation of Terconazole. European Experience, J. Reprod. Med., 34, 593
Cauwenbergh, 1989, Terconazole. Pharmacology of a new antimycotic agent, J. Reprod. Med., 34, 588
Sood, 2000, Terconazole cream for Non-Candida Albicans Fungal vaginitis: Results of a Retrospective Analysis, Infect. Dis. Obstet. Gynecol., 8, 240, 10.1002/1098-0997(2000)8:5<240::AID-IDOG1026>3.0.CO;2-4
Raab, 1985, Terconazole, ein neues Triazolderivaat zur Behandlung vaginaler Mykosen, Gynäk. Rdsch., 25, 197
Heel, 1982, Ketoconazole: A Review of its Therapeutic Efficacy in Superficial Fungal Infections, Drugs, 23, 1, 10.2165/00003495-198223010-00001
Aerts, 1980, The activity of ketoconazole in mixed cultures of leukocytes and Candida albicans, Sabouraudia, 18, 197, 10.1080/00362178085380351
Strippoli, 1997, Antifungal Activity of Ketoconazole and Other Azoles against Mallassezia furfur In vitro and In vivo, Infection, 25, 303, 10.1007/BF01720401
Borelli, 1979, Ketoconazole, an oral antifungal: laboratory and clinical assessment of imidazole drugs, Postgrad. Med. J., 55, 657, 10.1136/pgmj.55.647.657
Levine, 1978, Oral therapy for experimental coccidiodomycosis with R41400 (ketoconazole), a new imidazole, Am. Rev. Respir. Dis., 118, 715, 10.1164/arrd.1978.118.4.715
Williams, 1980, Suppression of Cryptococcosis and Histoplasmosis by Ketoconazole in Athymic Nude Mice, J. Infect. Dis., 141, 76, 10.1093/infdis/141.1.76
Huang, 1986, Pharmacokinetics and Dose Proportionality of Ketoconazole in Normal Volunteers, Antimicrob. Agents Chemother., 30, 206, 10.1128/AAC.30.2.206
Gascoigne, 1981, The kinetics of ketoconazole in animals and man, Clin. Res. Rev., 1, 177
1984, Drugs in Perspective, Ketoconazole, Mechanism of Action, Spectrum of Activity, Pharmacokinetics, Drug Interactions, Adverse Reactions and Therapeutic Use., Pharmacotherapy, 4, 343, 10.1002/j.1875-9114.1984.tb03398.x
Rosenblatt, 1980, Successful treatment of chronic mucocuteneous candidiasis with ketoconazole, J. Pediat., 97, 657, 10.1016/S0022-3476(80)80036-9
Smith, 1984, Ketoconazole: An Orally Efective Antifungal Agent, Mechanism of Action, Pharmacology, Clinical Efficacy and Adverse Effects, Pharmacotherapy, 4, 199, 10.1002/j.1875-9114.1984.tb03356.x
Calhoun, 1991, Treatment of Systemic Sporotrichosis with Ketoconazole, Rev. Infect. Dis., 13, 47, 10.1093/clinids/13.1.47
Van Cutsem, J., Van Gerven, F., Zaman, R., Heeres, J., and Janssen, P.A.J. (September, January 28). Pharmacological and preclinical results with a new oral and topical broad-spectrum antifungal, R51211. Processdings of 13th International Congress of Chemotherapy, Vienna, Austria.
Hoffman, 2000, Novel triazole antifungal agents, Exp. Opin. Invest. Drugs, 9, 593, 10.1517/13543784.9.3.593
Shadomy, 1984, In vitro studies with R 51,211, Antimicrob. Agents Chemother., 26, 5, 10.1128/AAC.26.1.5
Borgers, 1987, Degenerative changes in fungi after itraconazole treatment, Rev. Infect. Dis., 9, 33, 10.1093/clinids/9.Supplement_1.S33
1986, The In vivo Antifungal Activity of Broad-Spectrum Azoles, Drug Dev. Res., 8, 309, 10.1002/ddr.430080135
Lipp, 2008, Antifungal agents-clinical pharmacokinetics and drug interactions, Mycoses, 51, 7, 10.1111/j.1439-0507.2008.01523.x
Gubbins, 2007, Mould-active azoles: pharmacokinetics, drug interactions in neutropenic patients, Curr. Opin. Infect. Dis., 20, 579, 10.1097/QCO.0b013e3282f1be91
Kunze, 2006, Stereochemical aspects of itraconazole metabolism in vitro and in vivo, Drug Metab. Dispos., 34, 583, 10.1124/dmd.105.008508
Degreef, 1994, Current therapy of dermatophytosis, J. Am. Acad. Dermatol., 31, S25, 10.1016/S0190-9622(08)81263-7
Dockx, 1995, Pulse therapy with one-week itraconazole monthly for three or four months in the treatment of onychomycosis, Cutis, 56, 180
Cauwenbergh, 1986, New and prospective developments in antifungal drugs, Acta Derm. Venereol. Suppl. (Stockh.), 121, 147
Kauffman, 1994, Newer developments in therapy for endemic mycoses, Clin. Infect. Dis., 19, S28, 10.1093/clinids/19.Supplement_1.S28
Graybill, 2000, Changing Strategies for Treatment of Systemic Mycoses, Braz. J. Infect. Dis., 4, 47
Hughes, 1987, Action of fluconazole (UK-49,858) in relation to other systemic antifungal agents, J. Antimicrob. Chemother., 19, 171, 10.1093/jac/19.2.171
Odds, 1986, Antifungal effects of fluconazole (UK 49,858), a new triazole antifungal, in vitro, J. Antimicrob. Chemother., 18, 473, 10.1093/jac/18.4.473
Odds, 1988, Effects of azole antifungals in vitro on host/parasite interactions relevant to candida infections, J. Antimicrob. Chemother., 22, 473, 10.1093/jac/22.4.473
Nguyen, 1998, Voriconazole against fluconazole-susceptible and –resistant Candida isolates: in vitro efficacy compared with that of itraconazole and ketoconazole, J. Antimicrob. Chemother., 42, 253, 10.1093/jac/42.2.253
Nguyen, 1998, In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates, Antimicrob. Agents Chemother., 42, 253, 10.1093/jac/42.2.253
Classen, 1988, Treatment of Coccidioidal Meningitis with Fluconazole, J. Infect. Dis., 158, 903, 10.1093/infdis/158.4.903
Nagappan, 2007, Posaconazole: A Broad-Spectrum Triazole Antifungal agent, Clin. Infect. Dis., 45, 1610, 10.1086/523576
Manavathu, 2001, Isolation of in vitro susceptibility to amphotericin B, itraconazole and posaconazole of voriconazole-resistant laboratory isolates of Aspergillus fumigatus, Clin. Microb. Infect., 7, 130, 10.1046/j.1469-0691.2001.00220.x
Koltin, 1997, The search for new triazole antifungal agents, Curr. Opin. Chem. Biol., 1, 176, 10.1016/S1367-5931(97)80007-5
Gigolashvili, 1999, Update on Antifungal Therapy, Cancer Pract., 7, 157, 10.1046/j.1523-5394.1999.73011.x
Aperis, 2006, Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations, Expert Opin. Invest. Drugs, 15, 579, 10.1517/13543784.15.6.579
Dupont, 2003, Nouveaux antifongiques: voriconazole et caspofungine, Arch. de pédiatrie, 10, 592s, 10.1016/S0929-693X(03)90043-1
Barchiesi, 2001, In vitro Activity of Posaconazole against Clinical Isolates, J. Clin. Microbiol., 139, 4208, 10.1128/JCM.39.11.4208-4209.2001
Marco, 1998, In vitro activity of a new triazole antifungal agent, Sch 56592, against clinical isolates of filamentous fungi, Mycopathologia, 141, 73, 10.1023/A:1006970503053
Sugar, 1996, In vitro and In vivo Activities of SCH 56592 against Blastomyces dermatitidis, Antimicrob. Agents Chemother., 40, 1314, 10.1128/AAC.40.5.1314
Lutz, 1997, Activity of the Triazole SCH 56592 against Disseminated Murine Coccidiodomycosis, Antimicrob. Agents Chemother., 41, 1558, 10.1128/AAC.41.7.1558
Connolly, 2000, Comparison of a New triazole, Posaconazole with Itraconazole and Amphotericin B for Treatment of Histoplasmosis following Pulmonary Challenge in Immunocompromised Mice, Antimicrob. Agents Chemother., 44, 2604, 10.1128/AAC.44.10.2604-2608.2000
Connolly, 1999, Comparison of a New triazole Antifungal agent, Schering 56592 with Itraconazole and Amphotericin B for Treatment of Histoplasmosis in Immunocompetent Mice, Antimicrob. Agents Chemother., 43, 322, 10.1128/AAC.43.2.322
Cacciapuoti, 2000, In vitro and In vivo Activities of SCH 56592 (Posaconazole), a New Triazole Antifungal Agent, against Aspergillus and Candida, Antimicrob. Agents Chemother., 44, 2017, 10.1128/AAC.44.8.2017-2022.2000
Oakley, 1997, Efficacy of SCH-56592 in a Temporariy Neutropenic Murine Model of Invasive Aspergillosis with an Itraconazole-susceptible and Itraconazole-Resistant Isolate of Aspergillus fumigatus., Antimicrob. Agents Chemother., 41, 1504, 10.1128/AAC.41.7.1504
Graybill, 1998, SCH56592 treatment of murine invasive aspergillosis, J. Antimicrob. Chemother., 42, 539, 10.1093/jac/42.4.539
Arikan, 1999, Treatment of Murine Fusariosis with SCH 56592, Antimicrob. Agents Chemother., 43, 589, 10.1128/AAC.43.3.589
Nomeir, 2000, Pharmacokinetics of SCH 56592, a New Azole Broad-Spectrum Antifungal Agent, in Mice, Rats, Rabbits, Dogs, and Cynomolgus Monkeys., Antimicrob. Agents Chemother., 44, 727, 10.1128/AAC.44.3.727-731.2000
Krishna, 2006, Effect of a Nutritional Supplement on Posaconazolez Pharmacokinetics following Oral Administration to Healthy Volunteers, Antimicrob. Agents Chemother., 50, 1881, 10.1128/AAC.50.5.1881-1883.2006
Chhun, 2007, Simultaneous quantification of voriconazole and posaconazole in human plasma by high-performance liquid chromatography with ultra-violet detection, J. Chromatogr. B, 852, 223, 10.1016/j.jchromb.2007.01.021
Stevens, 2007, Posaconazole Therapy for Chronic Refractory Coccidiodomycosis, Chest, 132, 952, 10.1378/chest.07-0114
Walsh, 2007, Treatment of Invasive Aspergillosis with Posaconazole in Patients Who Are Refractory to or Intolerant of Conventional Therapy: An Externally Controlled Trial, Clin. Infect. Dis., 44, 2, 10.1086/508774
Raad, 2006, Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections, Clin. Infect. Dis., 42, 1726, 10.1086/504328
Hof, 2006, A new, broad-spectrum azole antifungal: posaconazole- mechanism of action and resistance, spectrum of activity, Mycoses, 49, 2, 10.1111/j.1439-0507.2006.01295.x
Marichal, 1991, Mode of action of anti-Candida drugs: Focus on terconazole and other ergosterol biosynthesis inhibitors, Am. J. Obstet. Gynecol., 165, 1193, 10.1016/S0002-9378(12)90726-7
Boiron, 1995, Azole Antifungals, Infect. Dis. Ther., 17, 327
McGinnis, 1985, Biochemical targets for antifungal azole derivatives: hypothesis on the mode of action, Current Topics in Medical Mycology, Volume 1, 131
Georgopapadakou, 1987, Effect of Antifungal Agents on Lipid Biosynthesis and Membrane Integraty in Candida albicans, Antimicrob. Agents Chemother., 31, 46, 10.1128/AAC.31.1.46
Lauwers, 1984, Molecular Basis for the Antimycotic and Antibacterial Activity of N-Substituted Imidazoles and Triazoles: the Inhibition of Isoprenoid Biosynthesis, Pestic. Sci., 15, 188, 10.1002/ps.2780150210
Sud, 1981, Mechanism of action of the antimycotic imidazoles, J. Invest. Dermatol., 76, 438, 10.1111/1523-1747.ep12521036
Beggs, 1994, Mechanism of the rapid methal action of miconazole and sulconazole against Candida albicans, Biochem. Arch., 10, 117
Beggs, 1987, Rapid fungicidal action of tioconazole and miconazole, Mycopathologica, 97, 187, 10.1007/BF00437242
Goossens, 1977, Cytochemical and biochemical studies of yeasts after in vitro exposure to miconazole, Antimicrob. Agents Chemother., 11, 500, 10.1128/AAC.11.3.500
Shigematsu, 1982, Effect of ketoconazole on isolated mitochondria from Candida albicans, Antimicrob. Agents Chemother., 21, 919, 10.1128/AAC.21.6.919
Niemegeers, 1981, Inhibition and Induction of Microsomal Enzymes in the Rat. A Comparative Study of Four Antimycotics: Miconazole, Econazole, Clotrimazole and Ketoconazole, Arch. Int. Pharmacodyn., 251, 26
Pfaller, 1990, Effects of Terconazole and Other Azole Antifungal Agents on the Sterol and Carbohydrate Composition of Candida Albicans, Diagn. Microbiol. Infect. Dis., 13, 31, 10.1016/0732-8893(90)90050-6
Talele, 1998, Docking Analysis of a Series of Cytochrome P-45014αDM Inhibiting Azole Antifungals, Drug Des. Discov., 15, 181
Tatele, 1999, Three-Dimensional Quantitative Structure-Activity Relationship (QSAR) and Receptor Mapping of Cytochrome P-45014αDM Inhibiting Azole Antifungal Agents, J. Chem. Inf. Comput. Sci., 39, 204, 10.1021/ci9800413
Lewis, 1999, Molecular modeling of lanosterol 14α-demethylase (CYP51) from Sacharomyces cerevisiae via homology with CYP102, a unique bacterial cytochrome P450 isoform: Quantitative Structure-Activity Relationships (QSARs) within two related series of antifungal azole derivatives, J. Enzyme Inhib., 14, 175, 10.3109/14756369909030315
Johnston, 2003, The pharmacokinetics of voriconazole, Br. J. Clin. Pharmacol., 56, 1, 10.1046/j.1365-2125.2003.01991.x
Chiou, 2000, New Drugs and Novel Targets for Treatment of Invasive Fungal Infections in Patients with Cancer, The Oncologist, 5, 120, 10.1634/theoncologist.5-2-120
Arias, 1996, Candida glabrata: In vitro susceptibility of 84 isolates to Eight Antifungal Agents, Chemotherapy, 42, 107, 10.1159/000239429
Niwano, 1995, Short-Term Therapy of Experimental Tinea Pedis in Guinea Pigs with Lanoconazole, a New Imidazole Antimycotic Agent, Antimicrob. Agents Chemother., 39, 2353, 10.1128/AAC.39.10.2353
Niwano, 1994, Therapeutic efficacy of Lanoconazole, a New Imidazole Antimycotic Agent, for Experimental Cuteneous Candidiasis in Guinea Pigs, Antimicrob. Agents Chemother., 38, 2204, 10.1128/AAC.38.9.2204
Ogata, 1983, 1-[1-[2-(3-Chlorobenzyl)oxy]phenyl]vinyl]-1H-imidazole Hydrochloride, a New Potent Antifungal Agent, J. Med. Chem., 26, 768, 10.1021/jm00359a026
Ogata, 1987, Synthesis and Antifungal Activity of New 1-Vinylimidazoles, J. Med. Chem., 30, 1348, 10.1021/jm00391a014
Mendez, 1999, In Vitro Susceptibilities of Clinical Yeast Isolates to the New Antifungal Eberconazole Compared with Their Susceptibilities to Clotrimazole and Ketoconazole Antimicrob, Agents Chemother., 43, 1258, 10.1128/AAC.43.5.1258
Enoch, 2006, Invasive fungal infections: a review of epidemiology and management options, J. Med. Microbiol., 55, 809, 10.1099/jmm.0.46548-0
Sahin, 2006, Treatment of invasive infections due to rare or emerging yeasts and moulds, Exp. Opin. Pharmacother., 7, 1181, 10.1517/14656566.7.9.1181
Nucci, 2003, Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients, Curr. Opin. infect. Dis., 16, 607, 10.1097/00001432-200312000-00015
Bartoli, 1998, New azole antifungals. 2. Synthesis and antifungal activity of heterocyclecarbocamide derivatives of 3-amino-2aryl-1-azolyl-2-butanol, J. Med. Chem., 41, 1855, 10.1021/jm970726e
Bartoli, 1998, New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones, J. Med. Chem., 41, 1869, 10.1021/jm9707277
Pasqualotto, 2010, Novel triazole antifungal drugs: focus on isavuconazole , ravuconazole and albaconazole, Curr. Opin. invest. D, 11, 165
Huczko, 1998, In vitro activity of a new oral triazole, BMS-207147 (ER-30346), Antimicrob. Agents Chemother., 42, 313, 10.1128/AAC.42.2.313
Minassian, 2003, In vitro activity of ravuconazole against zygomycetes, Scedosporium and Fusarium isolates, Clin. Microbiol. Infect., 9, 1250, 10.1111/j.1469-0691.2003.00755.x
Warn, 2006, In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp, Antimicrob. Agents Chemother., 57, 135, 10.1093/jac/dki399
Odds, 2006, Drug evaluation: BAL-8557--a novel broad-spectrum triazole antifungal, Curr. Opin. Invest. Drugs, 7, 766
Guinea, 2008, Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections, Future Microbiol., 3, 603, 10.2217/17460913.3.6.603
Odds, 2004, In vitro and in vivo activities of the novel azole antifungal agent R126638, Antimicrob. Agents Chemother., 48, 388, 10.1128/AAC.48.2.388-391.2004
Ausma, 2004, The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp. and Microsporum canis, Antimicrob. Agents Chemother., 48, 3272, 10.1128/AAC.48.9.3272-3278.2004
Meerpoel, 2005, Synthesis and in vitro and in vivo Structure-Activity Relationships of Novel Antifungal Triazoles for Dermatology, J. Med. Chem., 48, 2184, 10.1021/jm0494772
Geria, 2008, Pramiconazole, a triazole compound for the treatment of fungal infections, IDrugs, 11, 661
Ryder, 1992, Allylamine antifungal drugs, Curr. Top. Med. Mycol., 4, 158, 10.1007/978-1-4612-2762-5_6
2009, Terbinafine: a pharmacological and clinical review, Expert Opin. Pharmacother., 10, 2723, 10.1517/14656560903307462
Turner, 2006, Emerging echinocandins for treatment of invasive fungal infections, Expert Opin. Emerging Drugs, 11, 231, 10.1517/14728214.11.2.231
Odds, 2001, Sordarin antifungal agents, Expert Opin. Ther. Patents, 11, 283, 10.1517/13543776.11.2.283
1999, Sordarins as antifungal compounds, Curr. Opin. Anti-Infective Invest. Drugs, 1, 297
Richardson, 2008, Changing epidemiology of systemic fungal infections, Clin. Microbiol Infect., 14, 5, 10.1111/j.1469-0691.2008.01978.x
Pfaller, 2010, Epidemiology of Invasive Mycoses in North America, Critical Rev. Microbiol., 36, 1, 10.3109/10408410903241444
Bruggemann, 2009, Clinical Relevance of the Pharmacokinetic Interaction of Azole Antifungal drugs with Other Coadministered Agents, Clin. Infect. Dis., 48, 1441, 10.1086/598327
Hardin, 1988, Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob, Agents Chemother., 32, 1310, 10.1128/AAC.32.9.1310
Zhang, 2007, Advances in Topical and Systemic Antifungals, Dermatol. Clin., 25, 165, 10.1016/j.det.2007.01.002
Marichal, 1999, Contribution of mutations in the cytochrome-P450 14α -demethylase (Erg11p, cyp51p) to azole resistance in Candida albicans, Microbiology, 145, 2701, 10.1099/00221287-145-10-2701
Marichal, 1999, Mechanisms of resistance to azole antifungal compounds, Curr. Op. Anti-Infect. Invest. Drugs, 1, 318
Cannon, 2009, Efflux-mediated antifungal drug resistance, Clin. Microbiol. Rev., 22, 291, 10.1128/CMR.00051-08
Peman, 2009, Antifungal drug resistance mechanisms, Exp. Rev. Anti-Infect., 7, 453, 10.1586/eri.09.18
Hof, 2008, Is there a serious risk of resistance development to azoles among fungi due to the widespread use and long-term application of azole antifungals in medicine?, Drug Resist. Updates, 11, 25, 10.1016/j.drup.2008.01.001
Colombo, 2005, The ergosterol biosynthesis pathway, transporter genes, and azole resistance in Aspergillus fumigates, Med. Mycol., 43, S313, 10.1080/13693780400029114
Sanglard, 2002, Resistance of human fungal pathogens to antifungal drugs, Curr. Opin. Microbiol., 5, 379, 10.1016/S1369-5274(02)00344-2
Rex, 1997, Development of interpretive breakpoints for anti-fungal susceptibility testing: conceptual framework and analysis of in vitro/in vivo correlation data for fluconazole, itraconazole, and Candida infections, Clin. Infect. Dis., 24, 235, 10.1093/clinids/24.2.235
Odds, 1998, Should resistance to azole antifungals in vitro be interpreted as predicting clinical non-response?, Drug Resist. Updates, 1, 11, 10.1016/S1368-7646(98)80209-4
Bates, 2003, Clinical impact of drug-drug interactions with systemic azole antifungals, Drugs Today, 39, 801, 10.1358/dot.2003.39.10.799473
Girmenia, 2009, New generation azole antifungals in clinical investigation, Expert Opin. Invest. Drugs, 18, 1279, 10.1517/13543780903176407
Wang, 2002, Interaction of common azole antifungals with P glycoprotein, Antimicrob. Agents Chemother., 46, 160, 10.1128/AAC.46.1.160-165.2002